MCK McKesson Corporation
FY2025 10-K
McKesson Corporation (MCK) filed its fiscal year 2025 10-K annual report with the SEC on May 9, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model centered on government contracts requiring compliance with procurement laws and regulations
- • Emphasis on risks related to funding availability, contract renewal uncertainty, and heightened liability under government agreements
Management Discussion & Analysis
- • Revenue $310.5B, up 4.2% YoY from $297.9B driven by pharmaceutical distribution growth
- • Operating margin 2.3% vs 2.1% in prior year, reflecting improved supply chain efficiencies
Risk Factors
- • Opioid-related litigation liability $6.4 billion accrued as of March 31, 2025 with uncertainty on ultimate losses or resolution timing
- • Geopolitical exposure to U.S. healthcare market via largest customer CVS Health accounting for 24% of revenue and 23% of receivables
Financial SummaryXBRL
Revenue
$359.1B
Net Income
$3.3B
Gross Margin
3.7%
Operating Margin
1.2%
Net Margin
0.9%
ROE
-158.9%
Total Assets
$75.1B
EPS (Diluted)
$25.72
Operating Cash Flow
$6.1B
Source: XBRL data from McKesson Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on McKesson Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.